Janssen CarePath and Janssen Compass® are becoming J&J withME. Our name may be changing. Our commitment to patients stays the same.

For your patients today and tomorrow

Johnson & Johnson's broad portfolio of immunotherapies is leading the way

With 5 options across multiple lines of therapy, Johnson & Johnson is focused on helping you manage your patients

First anti-CD38 mAb; administered as intravenous infusion¹

First and only combination of anti-CD38 mAb and hyaluronidase-fihj; given as a subcutaneous injection²

Discover more

BCMA-directed CAR-T therapy; delivered as a single infusion³*

*Although delivered as a single infusion, therapy with CARVYKTI® is part of a multi-step process.³

Discover more

First-in-class BCMAxCD3-directed
bispecific antibody; given as
a subcutaneous injection^4,5

Discover more

First-in-class GPRC5DxCD3-
directed bispecific antibody; given
as a subcutaneous injection^6,7

Discover more

BCMA=B-cell maturation antigen; CAR-T=chimeric antigen receptor T cell; CD3=cluster of differentiation 3; CD38=cluster of differentiation 38; GPRC5D=G-protein-coupled receptor, class C, group 5, member D; mAb=monoclonal antibody.

CARVYKTI® (ciltacabtagene autoleucel) is developed and co-marketed with Legend Biotech.